Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Breast Cancer

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

The latest EMBER-3 readout points to meaningful delays before chemotherapy for patients progressing after aromatase inhibitors.

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy